Tranexamic Acid in Total Knee Replacement
Osteo Arthritis Knee
About this trial
This is an interventional treatment trial for Osteo Arthritis Knee focused on measuring total knee arthroplasty, tranexamic acid, without tourniquet, blood loss, function, multiple doses
Eligibility Criteria
Inclusion Criteria:
- varus deformity less than 10o
- lack of extension not more than 10o
- flexion of at least 90o.
Exclusion Criteria:
- uncontrolled medical diseases/comorbidities
- allergy and/or hypersensitivity to TXA
- a known history of thromboembolic disease, cardiovascular disease
- coronary or vascular stent placed within the past 12 months
- cerebral vascular disease (a history of stroke)
- subarachnoid hemorrhage
- preoperative coagulopathy (a platelet [PLT] count <150,000/mm3 or an international normalized ratio greater than 1.5
- preoperative renal or hepatic dysfunction
- retinal vein or artery occlusion
- patients with anemia (<12 g/dL for female, <13 g/dL for male)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Group A - Tranexamic Acid
Group B - Tranexamic Acid
Group C - Tranexamic Acid
1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively